Cabaletta Bio

CABA

Biotechnology · Healthcare

Price

$3.13

-0.06 (-1.88%)

Market Cap

$510.4M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+297.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 25.7M (2021) → 102.3M (2025)

Winston Score History

The full picture

Cabaletta Bio is a clinical-stage biotechnology company working on treatments for serious autoimmune diseases. These are conditions where the body's immune system mistakenly attacks itself, causing damage to organs and tissues. The company's main focus is on using engineered immune cells, called CAR-T cells, to target and eliminate the specific cells responsible for driving diseases like lupus and myasthenia gravis.

Cabaletta does not yet sell any products, so it earns no revenue today. It funds its research through cash raised from investors and, at times, partnerships with larger pharmaceutical companies. The company operates primarily in the United States and is considered small, with a market cap around $600 million. Its main competitive edge is its focus on a specific type of immune cell targeting, but the biggest risk is that its experimental treatments could fail in clinical trials, which would significantly threaten the company's future.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+53.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$143M/ year

↑ Rising (+47% vs prior year)

R&D investment increasing — building for the future

Insider Activity

12.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~16 months

$225M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-88.1%

Weak — -88.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial